Role of the mTOR‑FOXO1 pathway in obesity‑associated renal tubulointerstitial inflammation

Sun,Hong; Shao,Xinyu; He,Jiajia; Golos,Michal; Shi,Bimin

doi:10.3892/mmr.2018.9727

Role of the mTOR‑FOXO1 pathway in obesity‑associated renal tubulointerstitial inflammation

Authors:
- Hong Sun
- Xinyu Shao
- Jiajia He
- Michal Golos
- Bimin Shi
View Affiliations

Affiliations: Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China, Department of Oncology, The Third Affiliated Hospital of Soochow University, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213000, P.R. China, Centre for Amyloidosis and Acute Phase Protein, Division of Medicine, University College London (UCL), London NW3 2PF, UK
Published online on: December 5, 2018 https://doi.org/10.3892/mmr.2018.9727
Pages: 1284-1293

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since obesity is largely responsible for the growing incidence of renal tubulointerstitial inflammation, exploration into the mechanisms of obesity‑associated tubulointerstitial inflammation is essential. Studies have demonstrated that mammalian target of rapamycin (mTOR) is a crucial molecule in the pathogenesis of renal inflammation, including regulating the expression of inflammatory factors. The purpose of the present study was to further elucidate the role of mTOR in obesity‑associated tubulointerstitial inflammation. In the clinical study, obese and healthy subjects were recruited for physical examination, as well as the collection of blood and urine samples. Further study was performed on a high fat diet (HFD)‑induced obese rat model and a cultured human renal tubular epithelial cell line (HK‑2). The clinical study demonstrated that the participants with obesity had increased serum lipids, creatinine (Cr), urinary albumin to creatinine ratio (UACR) and urinary neutrophil gelatinase‑associated lipocalin (u‑NGAL). Moreover, the level of urinary monocyte chemoattractant protein‑1 (u‑MCP‑1) was increased in the participants with obesity, and it was positively correlated with free fatty acid (FFA), UACR and u‑NGAL. In the in vivo study, the results indicated that the levels of serum lipids, Cr and blood urea nitrogen (BUN), as well as 24 h urine protein and u‑NGAL, were signiﬁcantly increased in the HFD‑fed obese rats. In addition, the infiltration of CD68+ cells into the renal interstitial area and the release of interleukin‑1β (IL‑1β) was observed in the kidneys of obese rats. Meanwhile, the supernatant from HK‑2 cells treated with palmitic acid stimulated THP‑1 monocyte migration. The upregulation of MCP‑1, phosphorylated forkhead boxO1 (p‑FOXO1), and phosphorylated mTOR (p‑mTOR) was observed in vivo and in vitro. However, inhibition of mTOR was able to alleviate the above effects. Overall, these results demonstrated that activated mTOR induced FOXO1 phosphorylation, which mediates renal MCP‑1 release, causes tubulointerstitial inflammation and ultimately leads to pathological renal changes and dysfunction. However, inhibition of mTOR may play a renoprotective role during the progression of obesity‑associated tubulointerstitial inflammation.

View Figures

View References

1	Chade AR and Hall JE: Role of the renal microcirculation in progression of chronic kidney injury in obesity. Am J Nephrol. 44:354–367. 2016. View Article : Google Scholar : PubMed/NCBI
2	Declèves AE and Sharma K: Obesity and kidney disease: Differential effects of obesity on adipose tissue and kidney inflammation and fibrosis. Curr Opin Nephrol Hypertens. 24:28–36. 2015. View Article : Google Scholar : PubMed/NCBI
3	Redon J and Lurbe E: The kidney in obesity. Curr Hypertens Rep. 17:5552015. View Article : Google Scholar : PubMed/NCBI
4	Li LC, Yang JL, Lee WC, Chen JB, Lee CT, Wang PW, Vaghese Z and Chen WY: Palmitate aggravates proteinuria-induced cell death and inflammation via CD36-inflammasome axis in the proximal tubular cells of obese mice. Am J Physiol Renal Physiol. Sep 19–2018.(Epub ahead of print). doi: 10.1152/ajprenal.00536.2017. View Article : Google Scholar
5	Li A, Wang J, Zhu D, Zhang X, Pan R and Wang R: Arctigenin suppresses transforming growth factor-β1-induced expression of monocyte chemoattractant protein-1 and the subsequent epithelial-mesenchymal transition through reactive oxygen species-dependent ERK/NF-κB signaling pathway in renal tubular epithelial cells. Free radical research. 49:1095–1113. 2015. View Article : Google Scholar : PubMed/NCBI
6	Lv LL, Feng Y, Wen Y, Wu WJ, Ni HF, Li ZL, Zhou LT, Wang B, Zhang JD, Crowley SD and Liu BC: Exosomal CCL2 from tubular epithelial cells is critical for albumin-induced tubulointerstitial inflammation. J Am Soc Nephrol. 29:919–935. 2018.PubMed/NCBI
7	Fu CP, Lee IT, Sheu WH, Lee WJ, Liang KW, Lee WL and Lin SY: The levels of circulating and urinary monocyte chemoattractant protein-1 are associated with chronic renal injury in obese men. Clin Chim Acta. 413:1647–1651. 2012. View Article : Google Scholar : PubMed/NCBI
8	Lu X, Yin D, Zhou B and Li T: miR-135a promotes inflammatory responses of vascular smooth muscle cells from db/db mice via downregulation of FOXO1. Int Heart J. 59:170–179. 2018. View Article : Google Scholar : PubMed/NCBI
9	Xing YQ, Li A, Yang Y, Li XX, Zhang LN and Guo HC: The regulation of FOXO1 and its role in disease progression. Life Sci. 193:124–131. 2018. View Article : Google Scholar : PubMed/NCBI
10	Puthanveetil P, Wan A and Rodrigues B: FoxO1 is crucial for sustaining cardiomyocyte metabolism and cell survival. Cardiovasc Res. 97:393–403. 2013. View Article : Google Scholar : PubMed/NCBI
11	Maiese K, Chong ZZ, Hou J and Shang YC: The ‘O’ class: Crafting clinical care with FoxO transcription factors. Adv Exp Med Biol. 665:242–260. 2009. View Article : Google Scholar : PubMed/NCBI
12	Qin G, Zhou Y, Guo F, Ren L, Wu L, Zhang Y, Ma X and Wang Q: Overexpression of the FoxO1 ameliorates mesangial cell dysfunction in male diabetic rats. Mol Endocrinol. 29:1080–1091. 2015. View Article : Google Scholar : PubMed/NCBI
13	Du M, Wang Q, Li W, Ma X, Wu L, Guo F, Zhao S, Huang F, Wang H and Qin G: Overexpression of FOXO1 ameliorates the podocyte epithelial-mesenchymal transition induced by high glucose in vitro and in vivo. Biochem Biophys Res Commun. 471:416–422. 2016. View Article : Google Scholar : PubMed/NCBI
14	Hsu CK, Lin CC, Hsiao LD and Yang CM: Mevastatin ameliorates sphingosine 1-phosphate-induced COX-2/PGE2-dependent cell migration via FoxO1 and CREB phosphorylation and translocation. Br J Pharmacol. 172:5360–5376. 2015. View Article : Google Scholar : PubMed/NCBI
15	Li X, Zhang X, Pan Y, Shi G, Ren J, Fan H, Dou H and Hou Y: mTOR regulates NLRP3 inflammasome activation via reactive oxygen species in murine lupus. Acta Biochim Biophys Sin (Shanghai). 50:888–896. 2018. View Article : Google Scholar : PubMed/NCBI
16	Zhang X, Howell GM, Guo L, Collage RD, Loughran PA, Zuckerbraun BS and Rosengart MR: CaMKIV-dependent preservation of mTOR expression is required for autophagy during lipopolysaccharide-induced inflammation and acute kidney injury. J Immunol. 193:2405–2415. 2014. View Article : Google Scholar : PubMed/NCBI
17	Jiang H, Westerterp M, Wang C, Zhu Y and Ai D: Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice. Diabetologia. 57:2393–2404. 2014. View Article : Google Scholar : PubMed/NCBI
18	Paschoal VA, Amano MT, Belchior T, Magdalon J, Chimin P, Andrade ML, Ortiz-Silva M, Castro É, Yamashita AS, Rosa Neto JC, et al: mTORC1 inhibition with rapamycin exacerbates adipose tissue inflammation in obese mice and dissociates macrophage phenotype from function. Immunobiology. 222:261–271. 2017. View Article : Google Scholar : PubMed/NCBI
19	Perl A: mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci. 1346:33–44. 2015. View Article : Google Scholar : PubMed/NCBI
20	Yang P, Xiao Y, Luo X, Zhao Y, Zhao L, Wang Y, Wu T, Wei L and Chen Y: Inflammatory stress promotes the development of obesity-related chronic kidney disease via CD36 in mice. J Lipid Res. 58:1417–1427. 2017. View Article : Google Scholar : PubMed/NCBI
21	Wang B, Ding W, Zhang M, Li H and Gu Y: Rapamycin attenuates aldosterone-induced tubulointerstitial inflammation and fibrosis. Cell Physiol Biochem. 35:116–125. 2015. View Article : Google Scholar : PubMed/NCBI
22	Lu Y, Cheng J, Chen L, Li C, Chen G, Gui L, Shen B and Zhang Q: Endoplasmic reticulum stress involved in high-fat diet and palmitic acid-induced vascular damages and fenofibrate intervention. Biochem Biophys Res Commun. 458:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
23	Mu Y, Yin TL, Yin L, Hu X and Yang J: CTRP3 attenuates high-fat diet-induced male reproductive dysfunction in mice. Clin Sci (Lond). 132:883–899. 2018. View Article : Google Scholar : PubMed/NCBI
24	Ting SM, Nair H, Ching I, Taheri S and Dasgupta I: Overweight, obesity and chronic kidney disease. Nephron Clin Pract. 112:C121–C127. 2009. View Article : Google Scholar : PubMed/NCBI
25	Haller H, Bertram A, Nadrowitz F and Menne J: Monocyte chemoattractant protein-1 and the kidney. Curr Opin Nephrol Hypertens. 25:42–49. 2016. View Article : Google Scholar : PubMed/NCBI
26	Lv W, Booz GW, Wang Y, Fan F and Roman RJ: Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets. Eur J Pharmacol. 820:65–76. 2018. View Article : Google Scholar : PubMed/NCBI
27	Chen P, Shi X, Xu X, Lin Y, Shao Z, Wu R and Huang L: Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model. Diabetes Res Clin Pract. 137:173–182. 2018. View Article : Google Scholar : PubMed/NCBI
28	Hong YA, Bae SY, Ahn SY, Kim J, Kwon YJ, Jung WY and Ko GJ: Resveratrol ameliorates contrast induced nephropathy through the activation of SIRT1-PGC-1α-Foxo1 signaling in mice. Kidney Blood Press Res. 42:641–653. 2017. View Article : Google Scholar : PubMed/NCBI
29	Mehaffey E and Majid DSA: Tumor necrosis factor-α, kidney function, and hypertension. Am J Physiol Renal Physiol. 313:F1005–F1008. 2017. View Article : Google Scholar : PubMed/NCBI